Formulation and evaluation of mucoadhesive chitosan microspheres of carvedilol for nasal administration

The aim of this study was to develop and characterize chitosan microspheres Carvedilol (CRV) for nasal delivery improve bioavailability treatment hypertension angina pectoris. comes under BCS class II, is poorly water soluble drug highly permeable. Solubility determined by shaking flask method lipophilicity separating funnel method. route very convenient achieving high reduce hepatic first pass metabolism. Chitosan obtained from chitin fish, biodegradable nontoxic that suitable administration. were prepared cross- linking using glutaraldehyde as cross agent preparation evaluated size, entrapment efficiency (EE), in vitro mucoadhesion, release. mucoadhesive property also wash off test. spherical with size 15-40 micron, which favorable intranasal absorption. EE observed 40% 88% while percentage mucoadhesion 74%to 88%. A strong interaction between mucin detected explaining absorption electrostatic interaction. released around 80% 6h. It concluded could be used deliver CRV following administration improving the bioavailability.